(Q82254232)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20013267%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

title

Anti-TNF therapies: a comprehensive analysis of adverse effects associated with immunosuppression (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20013267%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

author name string

Victoria Connor

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20013267%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

publication date

16 December 2009

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20013267%20AND%20SRC:MED&resulttype=core&format=json

Rheumatology International

15 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20013267%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

volume

31

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20013267%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

issue

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20013267%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

page(s)

327-337

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20013267%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1007/s00296-009-1292-x

15 January 2020

exact match

0 references

cites work

Demyelinating and neurologic events reported in association with tumor necrosis factor alpha antagonism: by what mechanisms could tumor necrosis factor alpha antagonists improve rheumatoid arthritis but exacerbate multiple sclerosis?

1 reference

12 December 2020

Tumor necrosis factor antagonists: different kinetics and/or mechanisms of action may explain differences in the risk for developing granulomatous infection

1 reference

12 December 2020

Autoantibody production in patients treated with anti-TNF-alpha

1 reference

12 December 2020

Anti-tumour necrosis factor-alpha therapy in heart failure: future directions

1 reference

12 December 2020

Biologic therapy in clinical practice: enthusiasm must be tempered by caution

1 reference

12 December 2020

Tumour necrosis factor antagonists: structure, function, and tuberculosis risks

1 reference

12 December 2020

Adverse reactions to biologic agents: focus on autoimmune disease therapies

1 reference

12 December 2020

Tumor necrosis factor and granuloma biology: explaining the differential infection risk of etanercept and infliximab

1 reference

12 December 2020

Problems encountered during anti-tumour necrosis factor therapy

1 reference

12 December 2020

New drugs for rheumatoid arthritis

1 reference

12 December 2020

Serious bacterial infections in patients with rheumatoid arthritis under anti-TNF-alpha therapy

1 reference

12 December 2020

Complications and adverse reactions in the use of newer biologic agents

1 reference

12 December 2020

Biologics and heart failure in rheumatoid arthritis: are we any wiser?

1 reference

12 December 2020

Side effects of anti-TNF therapy: current knowledge.

1 reference

12 December 2020